Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

被引:98
|
作者
Norman, Jill [1 ]
机构
[1] UCL Med Sch, Div Med, UCL Ctr Nephrol, London NW3 2PF, England
关键词
Fibroblasts; Myofibroblasts; Fibrosis; Extracellular matrix; Epithelial-fibroblast interactions; Chronic kidney disease; ABNORMAL EXTRACELLULAR-MATRIX; GELATINASE-A MMP-2; MESENCHYMAL TRANSITION; CELL-PROLIFERATION; PKD1; GENE; INTERSTITIAL FIBROSIS; TARGETED DISRUPTION; TISSUE INHIBITOR; EPITHELIAL-CELLS; RENAL FIBROSIS;
D O I
10.1016/j.bbadis.2011.06.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The age on onset of decline in renal function and end-stage renal disease (ESRD) in autosomal polycystic kidney disease (ADPKD) is highly variable and there are currently no prognostic tools to identify patients who will progress rapidly to ESRD. In ADPKD, expansion of cysts and loss of renal function are associated with progressive fibrosis. Similar to the correlation between tubulointerstitial fibrosis and progression of chronic kidney disease (CKD), in ADPKD, fibrosis has been identified as the most significant manifestation associated with an increased rate of progression to ESRD. Fibrosis in CKD has been studied extensively. In contrast, little is known about the mechanisms underlying progressive scarring in ADPKD although some commonality may be anticipated. Current data suggest that fibrosis associated with ADPKD shares at least some of the "classical" features of fibrosis in CKD (increased interstitial collagens, changes in matrix metalloproteinases (MMPs), over-expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), over-expression of plasminogen activator inhibitor-1 (PAI-1) and increased transforming growth factor beta (TGF beta) but that there are also some unique and stage-specific features. Epithelial changes appear to precede and to drive interstitial changes leading to the proposal that development of fibrosis in ADPKD is biphasic with alterations in cystic epithelia precipitating changes in interstitial fibroblasts and that reciprocal interactions between these cell types drives progressive accumulation of extracellular matrix (ECM). Since fibrosis is a major component of ADPKD it follows that preventing or slowing fibrosis should retard disease progression with obvious therapeutic benefits. The development of effective anti-fibrotic strategies in ADPKD is dependent on understanding the precise mechanisms underlying initiation and progression of fibrosis in ADPKD and the role of the intrinsic genetic defect in these processes. This article is part of a Special Issue entitled: Polycystic Kidney Disease. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:1327 / 1336
页数:10
相关论文
共 50 条
  • [1] DEVELOPMENT OF A MODEL TO PREDICT DISEASE PROGRESSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    McEwan, P.
    Wilton, Bennett H.
    Robinson, P.
    Hadimeri, H.
    Ong, A.
    Orskov, B.
    Peces, R.
    Sandford, R.
    Scolari, F.
    Walz, G.
    Woon, C.
    O'Reilly, K.
    VALUE IN HEALTH, 2014, 17 (07) : A564 - A564
  • [2] DEVELOPMENT OF A MODEL TO PREDICT DISEASE PROGRESSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    Robinson, P.
    McEwan, P.
    Hadimeri, H.
    Ong, A. C. M.
    Orskov, B.
    Peces, R.
    Sandford, R.
    Scolari, F.
    Walz, G.
    Cooke, Claire
    O'Reilly, K.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 75 - 75
  • [3] Autosomal dominant polycystic kidney disease (ADPKD) in children
    Crocker, J.
    Acott, P.
    PEDIATRIC NEPHROLOGY, 2008, 23 (09) : 1653 - 1653
  • [4] A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model
    Phil McEwan
    Hayley Bennett Wilton
    Albert C. M. Ong
    Bjarne Ørskov
    Richard Sandford
    Francesco Scolari
    Maria-Cristina V. Cabrera
    Gerd Walz
    Karl O’Reilly
    Paul Robinson
    BMC Nephrology, 19
  • [5] A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model
    McEwan, Phil
    Wilton, Hayley Bennett
    Ong, Albert C. M.
    Orskov, Bjarne
    Sandford, Richard
    Scolari, Francesco
    Cabrera, Maria-Cristina V.
    Walz, Gerd
    O'Reilly, Karl
    Robinson, Paul
    BMC NEPHROLOGY, 2018, 19
  • [6] Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview
    Corradi, V.
    Gastaldon, F.
    Virzi, G. M.
    Caprara, C.
    Martino, F.
    Ronco, C.
    MINERVA MEDICA, 2015, 106 (01) : 53 - 64
  • [7] Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)
    Sans-Atxer, Laia
    Torra, Roser
    Fernandez-Llama, Patricia
    CLINICAL KIDNEY JOURNAL, 2013, 6 (05) : 457 - 463
  • [8] Extrarenal manifestations of autosomal dominant polycystic kidney disease (ADPKD)
    Harutyunyan, S.
    Andreeva, E.
    Savenkova, N.
    Larionova, V.
    Leviashvili, G.
    PEDIATRIC NEPHROLOGY, 2011, 26 (09) : 1691 - 1691
  • [9] Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Cadnapaphornchai, Melissa A.
    CURRENT HYPERTENSION REVIEWS, 2013, 9 (01) : 21 - 26
  • [10] Role of GREMLIN in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Tejedor, Lucia
    Cordido, Adrian
    Marquez-Exposito, Laura
    Nunez-Gonzalez, Laura
    Marchant, Vanessa
    Sanz, Ana B.
    Ortiz, Alberto
    Garcia-Gonzalez, Miguel A.
    Ruiz-Ortega, Marta
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 397 - 397